KR20030051802A - Nutritional composition for an immune condition - Google Patents

Nutritional composition for an immune condition Download PDF

Info

Publication number
KR20030051802A
KR20030051802A KR10-2003-7006389A KR20037006389A KR20030051802A KR 20030051802 A KR20030051802 A KR 20030051802A KR 20037006389 A KR20037006389 A KR 20037006389A KR 20030051802 A KR20030051802 A KR 20030051802A
Authority
KR
South Korea
Prior art keywords
vitamin
composition
composition according
calcium
zinc
Prior art date
Application number
KR10-2003-7006389A
Other languages
Korean (ko)
Inventor
에블린 스피베이-크로배쓰
끌로드 까바디니
퍼르디낸드 하쉬케
베로니끄 죠쌍
에두아르도 쉬프린
Original Assignee
소시에떼 데 프로듀이 네슬레 소시에떼아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030051802(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 소시에떼 데 프로듀이 네슬레 소시에떼아노님 filed Critical 소시에떼 데 프로듀이 네슬레 소시에떼아노님
Publication of KR20030051802A publication Critical patent/KR20030051802A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • A61K38/012Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018Hydrolysed proteins; Derivatives thereof from animals from milk
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1307Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/13Fermented milk preparations; Treatment using microorganisms or enzymes using additives
    • A23C9/1322Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/065Microorganisms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/244Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from corms, tubers or roots, e.g. glucomannan
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • A23L33/155Vitamins A or D
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/30Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20Milk; Whey; Colostrum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

면역 상태의 예방 또는 치료를 위한 영양 조성물이 기술된다. 넓은 의미로, 이는 적어도 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연, 셀레늄, 프룩토올리고당 및/또는 이눌린, 균활성 젖산 박테리아를 함유한다. 예를 들어, 한 구현예에서 이는 300 g 당 150 IU 비타민 E, 120 ㎎ 비타민 C, 2 ㎎ 비타민 B6, 400 ㎍ 엽산, 3.8 ㎍ 비타민 B12, 1.5 ㎎ 구리, 15 ㎎ 아연, 1000 ㎍ 셀레늄, 3 g 프룩토올리고당 및/또는 이눌린, 10 E10 cfu ST11 락토바실루스를 함유한다. 이의 제조 방법; 기능성 식품 또는 의약의 제조에서의 이의 용도; 및 유효량의 조성물을 투여하는 것을 포함하는 면역 상태의 예방 또는 치료 방법이 기술된다.Nutritional compositions for the prevention or treatment of an immune condition are described. In a broad sense, it contains at least vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc, selenium, fructooligosaccharides and / or inulin, a bactericidal lactic acid bacterium. For example, in one embodiment it is 150 IU vitamin E per 300 g, 120 mg vitamin C, 2 mg vitamin B6, 400 μg folic acid, 3.8 μg vitamin B12, 1.5 mg copper, 15 mg zinc, 1000 μg selenium, 3 g Fructooligosaccharide and / or inulin, 10 E10 cfu ST11 lactobacillus. Its preparation method; Its use in the manufacture of functional foods or medicaments; And methods for preventing or treating an immune condition comprising administering an effective amount of the composition.

Description

면역 상태용 영양 조성물 {NUTRITIONAL COMPOSITION FOR AN IMMUNE CONDITION}NUTRITIONAL COMPOSITION FOR AN IMMUNE CONDITION}

본 발명은 면역 상태의 예방 또는 치료를 위한 영양 조성물, 조성물의 제조 방법, 면역 상태의 예방 또는 치료를 위한 기능성 식품 또는 의약의 제조에서의 조성물의 용도, 및 유효량의 조성물을 투여하는 것을 포함하는 면역 상태의 치료 방법에 관한 것이다.The present invention provides a nutritional composition for the prevention or treatment of an immune condition, a method of making the composition, the use of the composition in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition, and an immune comprising administering an effective amount of the composition A method for treating a condition.

본 명세서에서, 용어 "함유한다"는 "특히 포함한다"를 의미한다. 이는 "단지 구성된다"는 것으로 해석되지 않는다.As used herein, the term "contains" means "including in particular." It is not to be interpreted as "only constructed".

본 명세서에서, 용어 "면역 상태"는 손상된 면역 반응, 염증 상태, 염증, 만성 질환 (예를 들어 관절염 또는 위염), 노화와 관련되어 염증성 반응의 증가에 이르는 상태로 구성되는 군으로부터 선택되는 병을 나타낸다.As used herein, the term “immune condition” refers to a disease selected from the group consisting of impaired immune response, inflammatory condition, inflammation, chronic disease (eg arthritis or gastritis), a condition leading to an increase in inflammatory response associated with aging. Indicates.

65 세 이상의 미국인은 전환기에 US 인구의 4 % 이상을 차지하였다; 현재, 이들은 인구의 12 % 이상을 초과한다. 그러나, 이들은 US 인구의 12 %를 차지하지만, 급성 병상 기간의 40 % 이상을 차지하고, 모든 처방 약물의 30 % 이상을 구입하며, US 보건 예산의 30 %를 소비한다. 또한, 2030년에는 7천만명의 미국인 (1:5)이 65세 이상일 것으로 추정되고, 85세 이상은 모든 연령군의 가장 높은 백분율 증가를 경험할 것으로 예상된다.Americans age 65 and older accounted for over 4% of the US population at the transition; At present, they exceed more than 12% of the population. However, they account for 12% of the US population, but account for more than 40% of acute beds, purchase more than 30% of all prescription drugs, and consume 30% of the US health budget. It is also estimated that 70 million Americans (1: 5) will be 65 or older by 2030, and those over 85 are expected to experience the highest percentage increase in all age groups.

인구의 평균 연령이 증가하면서, 영양적인 요구 및 치료와 관련된 노화의 독특한 면모를 더 잘 이해하는 것이 필수적이다. 많은 생리학적 기능이 성인 일생에 걸쳐 점진적으로 쇠퇴하고, 영양에 영향을 준다. 예를 들어, 기능 세포수에서의 감소 및 결과적인 대사 과정의 감속으로 중장년층에서 칼로리 요구량이 저하된다. 또한, 노화에 일반적으로 수반되는 신체 활동에서의 감소는 에너지 요구량을 추가로 저하시킨다. 중장년층 환자의 전체 칼로리 섭취를 단지 감소시키는 것은 이들의 요구되는 영양에 역효과를 미칠 수 있다. 전체 칼로리 섭취가 감소될 때, 남아있는 식품 섭취에서 단백질, 비타민 및 미네랄이 적절하게 균형되어 섭취되도록 주의하여여 한다. 중장년층에서 칼로리 섭취를 감소시키기 위해, "엠프티(empty)" 칼로리 (즉, 지방)의 소비는 감소될 수 있고, 고영양(nutrient-dense) 식품 (즉, 탄수화물 및 단백질)의 소비는 증가될 수 있다.As the average age of the population increases, it is essential to better understand the unique aspects of aging associated with nutritional needs and treatment. Many physiological functions gradually decline and affect nutrition throughout adult life. For example, the reduction in functional cell numbers and the resulting slowdown of metabolic processes lower the calorie requirement in the elderly. In addition, the reduction in physical activity normally associated with aging further lowers energy requirements. Only reducing the total calorie intake of older patients can adversely affect their required nutrition. When the total calorie intake is reduced, care should be taken to ensure that the protein, vitamins and minerals are properly balanced in the remaining food intake. To reduce calorie intake in the elderly, the consumption of “empty” calories (ie, fat) can be reduced, and consumption of high nutrient-dense foods (ie, carbohydrates and proteins) can be increased. Can be.

중년기의 영양 요구량이 성인의 것과 상이하지만, 건강 관리 환경에서, 표준 영양 제형물은 현재 사용되는 성분 영양의 1차 형태이다. 물론, 표준 제형물은 중장년층 환자의 영양 요구량을 고려하지 않는다. 표준 제품에는 중장년층 환자의 통상적인 결핍 및 대사 변화를 보완하기 위해 주요 미량영양소가 보충되어야 한다는 문제가 있다. 따라서, 중장년층 환자의 영양 요구량을 충족시키는 영양 조성물이 필요하다.Although middle age nutritional requirements differ from those of adults, in a health care environment, standard nutritional formulations are the primary form of ingredient nutrition currently used. Of course, the standard formulation does not take into account the nutritional needs of older patients. Standard products have the problem that major micronutrients must be replenished to compensate for the usual deficiencies and metabolic changes in older patients. Accordingly, there is a need for nutritional compositions that meet the nutritional needs of elderly patients.

상기 문제에 더하여, 중장년층에서 뿐만 아니라 임상 및 작업(performance) 환경에서, 예를 들어, 손상으로부터의 운동선수의 회복과 관련되어, 면역 상태의 문제를 다루기 위한 조성물이 요구된다.In addition to the above problems, there is a need for compositions to address the problem of immune status, as well as in the clinical and performance environment, for example, in relation to the recovery of athletes from injury.

또한, 식이요법 및 영양 보충제의 효과가 생존 및 삶의 질을 개선시키는데 기능할 수 있다는 것이 알려져 있다. 특히, 건강, 특히 면역 상태와 관련된 건강을 개선시킬 수 있는 영양 조성물이 필요하다.It is also known that the effects of diet and nutritional supplements can function to improve survival and quality of life. In particular, there is a need for nutritional compositions that can improve health, particularly health associated with immune conditions.

또한, 손상된 면역 반응의 문제가 노화, 만성 병리학적 상태 및/또는 영양실조와 관련될 수 있다는 것이 알려져 있다. 이러한 문제는 영양 보충제를 제공함으로써 부분적으로 다루어졌다. 그러나, 이러한 보충제들에는 이들이, 일반적으로, 특정 병에 특이적이고, 상태가 더욱 복잡하게 조합된 환자에게 양호한 영양 지원을 제공하지 않는다는 문제가 있다. 이는 중장년층 환자에 특히 관련된다. 게다가, 나이가 들면서 관절염, 위염 등과 같은 만성 질환의 가능성이 증가하여, 염증성 반응이 증가한다.It is also known that problems with impaired immune responses may be associated with aging, chronic pathological conditions and / or malnutrition. This problem has been addressed in part by providing nutritional supplements. However, these supplements have the problem that they generally do not provide good nutritional support to patients who are specific to a particular disease and have a more complex combination of conditions. This is particularly relevant for elderly patients. In addition, with age, the likelihood of chronic diseases such as arthritis, gastritis increases, and the inflammatory response increases.

또한, 전염성 설사 (로타바이러스 및 박테리아성 감염), 알레르기, 내장 완전성의 수복 및 유지, 박테리아 과성장, 내독혈증 및 장 침투성과 관련된 문제를 다루는 영양 조성물이 필요하다.There is also a need for nutritional compositions that address issues related to infectious diarrhea (rotavirus and bacterial infection), allergies, repair and maintenance of visceral integrity, bacterial overgrowth, endotoemia and intestinal permeability.

본 발명은 상기 제시된 문제들을 다룬다.The present invention addresses the problems presented above.

놀랍게도, 중장년층 환자에게 영양을, 뿐만 아니라 예를 들어 운동선수에게 작업 영양을, 또는 병원 환자에게 임상 영양을 제공하는데 사용될 수 있는 조성물을 발견하였다.Surprisingly, a composition has been found that can be used to provide nutrition for elderly patients, as well as for example, nutrition for athletes, or clinical nutrition for hospital patients.

따라서, 제 1 양상에서, 본 발명은 단백질 공급원, 탄수화물 공급원, 지방 공급원, 균활성 젖산 박테리아 및 추가적으로 프룩토올리고당 및/또는 이눌린을 함유하는 조성물을 제공한다.Thus, in a first aspect, the present invention provides a composition containing a protein source, a carbohydrate source, a fat source, a fungal lactic acid bacterium and additionally fructooligosaccharides and / or inulin.

제 2 양상에서, 본 발명은 필요한 영양소를 필요한 양으로 함께 배합하는 단계를 포함하는, 본 발명의 구현예에 따른 조성물의 제조 방법을 제공한다.In a second aspect, the present invention provides a method of preparing a composition according to an embodiment of the present invention, comprising combining the necessary nutrients together in the required amount.

제 3 양상에서, 본 발명은 면역 상태의 예방 또는 치료에서의 본 발명에 따른 조성물의 용도를 제공한다.In a third aspect, the present invention provides the use of a composition according to the invention in the prevention or treatment of an immune condition.

제 4 양상에서, 본 발명은 면역 상태의 예방 또는 치료를 위한 기능성 식품 또는 의약의 제조에서의 본 발명의 구현예에 따른 조성물의 용도를 제공한다.In a fourth aspect, the present invention provides the use of a composition according to an embodiment of the present invention in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition.

제 5 양상에서, 본 발명은 유효량의 본 발명의 구현예에 따른 조성물을 투여하는 것을 포함하는, 면역 상태의 예방 또는 치료 방법을 제공한다.In a fifth aspect, the invention provides a method of preventing or treating an immune condition comprising administering an effective amount of a composition according to an embodiment of the invention.

바람직하게는, 본 발명에 따른 조성물의 구현예는 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연 및 셀레늄으로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 함유한다. 더욱 바람직하게는, 2 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 더욱 더 바람직하게는, 3 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 가장 바람직하게는, 모든 이러한 미네랄 또는 영양소를 함유한다.Preferably, embodiments of the compositions according to the invention contain at least one nutrient or mineral selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium. More preferably, it contains two or more such nutrients or minerals. Even more preferably, it contains three or more such nutrients or minerals. Most preferably it contains all such minerals or nutrients.

바람직하게는, 본 발명의 따른 조성물의 구현예는 칼슘, 인, 마그네슘, 철, 비타민 A, 비타민 B1, 비타민 B2, 니아신 및 비타민 D로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 추가적으로 함유한다. 더욱 바람직하게는, 2 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 더욱 더 바람직하게는, 3 개 이상의 이러한 영양소 또는 미네랄을 함유한다. 가장 바람직하게는, 본 발명의 따른 조성물의 구현예는 모든 이러한 미네랄 또는 영양소를 함유한다.Preferably, embodiments of the compositions according to the invention additionally contain at least one nutrient or mineral selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. . More preferably, it contains two or more such nutrients or minerals. Even more preferably, it contains three or more such nutrients or minerals. Most preferably, embodiments of the compositions according to the invention contain all such minerals or nutrients.

바람직하게는, 본 발명에 따른 조성물의 구현예는 밀크 칼슘, 또는 밀크 칼슘으로부터 유래된 칼슘의 형태인 칼슘을 함유한다.Preferably, embodiments of the compositions according to the invention contain calcium in the form of milk calcium, or calcium derived from milk calcium.

바람직하게는, 본 발명에 따른 조성물의 구현예는 파라카제이(paracasei) 및 존스니이(johnsonii) 박테리아로 구성되는 군으로부터 선택되는 하나 이상의 균활성 젖산 박테리아를 함유한다. 더욱 바람직하게는, 본 발명에 따른 조성물의 구현예는 ST11 (명칭 NCCMI-2116으로 기탁됨) 및 La1 (명칭 NCCMI-1225로 기탁됨)으로 구성되는 군으로부터 선택되는 하나 이상의 균활성 젖산 박테리아를 함유한다.Preferably, an embodiment of the composition according to the invention contains at least one bactericidal lactic acid bacterium selected from the group consisting of paracasei and johnsonii bacteria. More preferably, embodiments of the compositions according to the invention contain at least one bacteriostatic lactic acid bacterium selected from the group consisting of ST11 (named NCCMI-2116) and La1 (named NCCMI-1225). do.

바람직하게는, 본 발명에 따른 조성물의 구현예는 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)을 함유한다. 바람직하게는 이는 1일 당 투여되는 조성물의 양이다.Preferably, embodiments of the composition according to the invention contain the following mass or amount of nutrients or minerals (if present) per 300 g of the composition. Preferably this is the amount of composition administered per day.

비타민 E: 바람직하게는 약 1 IU 내지 약 400 IU, 가장 바람직하게는 약 120 IUVitamin E: preferably about 1 IU to about 400 IU, most preferably about 120 IU

비타민 C: 바람직하게는 약 6 ㎎ 내지 약 300 ㎎, 가장 바람직하게는 약 120 ㎎Vitamin C: preferably about 6 mg to about 300 mg, most preferably about 120 mg

비타민 B6: 바람직하게는 약 0.17 ㎎ 내지 약 3 ㎎, 가장 바람직하게는 약 2 ㎎Vitamin B6: preferably about 0.17 mg to about 3 mg, most preferably about 2 mg

엽산: 바람직하게는 약 40 ㎍ 내지 약 800 ㎍, 가장 바람직하게는 약 400 ㎍Folic acid: preferably about 40 μg to about 800 μg, most preferably about 400 μg

비타민 B12: 바람직하게는 약 0.24 ㎎ 내지 약 5 ㎎, 가장 바람직하게는 약 3.8 ㎍Vitamin B12: preferably about 0.24 mg to about 5 mg, most preferably about 3.8 μg

구리: 바람직하게는 약 0.3 ㎎ 내지 약 3 ㎎, 가장 바람직하게는 약 1.5 ㎎Copper: preferably about 0.3 mg to about 3 mg, most preferably about 1.5 mg

아연: 바람직하게는 약 1.5 ㎎ 내지 약 15 ㎎, 가장 바람직하게는 약 15 ㎎Zinc: preferably about 1.5 mg to about 15 mg, most preferably about 15 mg

셀레늄: 바람직하게는 약 7 ㎍ 내지 약 300 ㎍, 가장 바람직하게는 약 100 ㎍Selenium: preferably about 7 μg to about 300 μg, most preferably about 100 μg

프룩토올리고당 및/또는 아카시아 고무: 바람직하게는 약 4 g 내지 약 50 g, 가장 바람직하게는 약 6 gFructooligosaccharides and / or acacia rubbers: preferably about 4 g to about 50 g, most preferably about 6 g

젖산 박테리아: 바람직하게는 약 10 E8 내지 약 10 E12 cfu. 가장 바람직하게는 약 10 E10 cfu.Lactic acid bacteria: preferably from about 10 E8 to about 10 E12 cfu. Most preferably about 10 E10 cfu.

바람직하게는, 본 발명에 따른 조성물의 구현예는 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)로부터 선택되는 하나 이상의 영양소를 함유한다. 바람직하게는, 이는 1일 당 투여되는 조성물의 양이다.Preferably, embodiments of the compositions according to the invention contain one or more nutrients selected from the following mass or amounts of nutrients or minerals (if present) per 300 g of the composition. Preferably, this is the amount of composition administered per day.

칼슘: 약 100 ㎎ 내지 약 300 ㎎, 더욱 바람직하게는 약 200 ㎎;Calcium: about 100 mg to about 300 mg, more preferably about 200 mg;

인: 약 50 ㎎ 내지 약 615 ㎍, 더욱 바람직하게는 약 150 ㎎;Phosphorus: about 50 mg to about 615 μg, more preferably about 150 mg;

마그네슘: 약 110 ㎎ 내지 약 210 ㎎, 더욱 바람직하게는 약 60 ㎎;Magnesium: about 110 mg to about 210 mg, more preferably about 60 mg;

비타민 A: 약 1000 IU 내지 약 1500 IU, 더욱 바람직하게는 약 1333 IU;Vitamin A: about 1000 IU to about 1500 IU, more preferably about 1333 IU;

비타민 D: 약 50 IU 내지 약 150 IU, 더욱 바람직하게는 약 100 IU;Vitamin D: from about 50 IU to about 150 IU, more preferably about 100 IU;

비타민 E: 약 5.0 IU 내지 약 150 IU, 더욱 바람직하게는 약 120 IU;Vitamin E: about 5.0 IU to about 150 IU, more preferably about 120 IU;

비타민 C: 약 30 ㎎ 내지 약 500 ㎎, 더욱 바람직하게는 약 120 ㎎;Vitamin C: about 30 mg to about 500 mg, more preferably about 120 mg;

비타민 B1: 약 0.1 ㎎ 내지 약 2 ㎎, 더욱 바람직하게는 약 0.25 ㎎;Vitamin B1: about 0.1 mg to about 2 mg, more preferably about 0.25 mg;

비타민 B2: 약 0.1 ㎎ 내지 약 0.6 ㎎, 더욱 바람직하게는 약 0.3 ㎎;Vitamin B2: about 0.1 mg to about 0.6 mg, more preferably about 0.3 mg;

니아신: 약 1.5 ㎎ 내지 약 7.2 ㎎, 더욱 바람직하게는 약 3 ㎎;Niacin: about 1.5 mg to about 7.2 mg, more preferably about 3 mg;

비타민 B6: 약 1.0 ㎎ 내지 약 3.0 ㎎, 더욱 바람직하게는 약 2 ㎎;Vitamin B6: about 1.0 mg to about 3.0 mg, more preferably about 2 mg;

엽산: 약 200 ㎍ 내지 약 600 ㎍, 더욱 바람직하게는 약 400 ㎍;Folic acid: about 200 μg to about 600 μg, more preferably about 400 μg;

비타민 B12: 약 1.5 ㎍ 내지 약 4.5 ㎍, 더욱 바람직하게는 약 3.8 ㎍;Vitamin B12: about 1.5 μg to about 4.5 μg, more preferably about 3.8 μg;

철: 약 2.0 ㎎ 내지 약 5 ㎎, 더욱 바람직하게는 2.75 ㎎; 및Iron: about 2.0 mg to about 5 mg, more preferably 2.75 mg; And

아연: 약 10 ㎎ 내지 약 20 ㎎, 더욱 바람직하게는 약 15 ㎎.Zinc: about 10 mg to about 20 mg, more preferably about 15 mg.

바람직하게는, 본 발명에 따른 조성물의 구현예는 아카시아 고무를 함유한다.Preferably, embodiments of the composition according to the invention contain acacia rubber.

바람직하게는, 본 발명에 따른 방법의 구현예는 영양소들을 필요한 양으로 배합하고 배합된 혼합물을 압출하는 단계를 포함한다. 더욱 바람직하게는, 혼합물을 분무 건조시키는 것을 포함한다.Preferably, an embodiment of the method according to the invention comprises combining the nutrients in the required amount and extruding the blended mixture. More preferably, spray drying the mixture.

본 발명의 장점은 즉석에서 물에 용해되어 음료 또는 수프를 제공할 수 있는 영양 조성물을 제공한다는 것이다. 이는 조리를 필요로 하지 않는다.An advantage of the present invention is that it provides a nutritional composition which can be readily dissolved in water to provide a beverage or soup. It does not require cooking.

본 발명의 또다른 장점은 면역 상태의 예방 또는 치료를 위해 식품에 개조되어 단순히 투여될 수 있는 단일 조성물을 제공한다는 것이다. 조성물은 임상 또는 작업 영양 환경에서 제공될 수 있고, 특히 중장년층 환자에 적절하다.Another advantage of the present invention is that it provides a single composition that can be modified and simply administered to food for the prevention or treatment of an immune condition. The composition may be provided in a clinical or occupational nutrition setting, and is particularly suitable for elderly patients.

균활성 박테리아에 의해 제공되는 장점은 병원성 박테리아에 의해 야기되는 설사의 예방 또는 저해; 로타바이러스에 의한 설사, 특히 장세포 감염의 예방 또는 저해; 설사를 야기하는 병원성 박테리아에 의한 장의 콜로니화의 저해; 및 숙주 생물의 장 점막에 부착하여 콜로니화시키는 능력이 포함된다.Advantages offered by fungal bacteria include the prevention or inhibition of diarrhea caused by pathogenic bacteria; Prevention or inhibition of diarrhea by rotavirus, particularly enteric cell infection; Inhibition of intestinal colonization by pathogenic bacteria causing diarrhea; And the ability to attach and colonize the intestinal mucosa of the host organism.

본 발명의 또다른 장점은 당뇨병에 이로운 조성물을 제공한다는 것이다. 이는 낮은 혈당 지수를 제공하는 다량영양소, 단백질, 탄수화물 및 지방의 특정 조성에 기인한다.Another advantage of the present invention is that it provides a composition that is beneficial to diabetes. This is due to the specific composition of macronutrients, proteins, carbohydrates and fats that provide low glycemic index.

본 발명의 추가적인 특징 및 장점은 하기 제공되는 현재 바람직한 구현예의상세한 설명에 기술되고, 이로부터 명백해질 것이다.Additional features and advantages of the invention will be described in and will become apparent from the detailed description of the presently preferred embodiments provided below.

명쾌함 및 간결한 기술을 위해, 동일한 또는 별도의 구현예의 일부로서 특징들이 본원에 기술되지만, 본 발명의 범주에는 모든 또는 일부 기술된 특징들이 조합된 구현예가 포함될 수 있다는 것이 명백할 것이다.For clarity and concise description, features are described herein as part of the same or separate embodiments, but it will be apparent that the scope of the invention may include embodiments in which all or some of the described features are combined.

한 구현예에서, 영양 조성물은 단백질 공급원을 함유한다. 단백질 공급원은 바람직하게는 영양 제형물의 에너지의 약 5 % 내지 약 55 %를 제공한다; 예를 들어 에너지의 약 20 % 내지 약 50 %, 바람직하게는 약 26 %. 식이 단백질이 단백질 공급원으로 바람직하다. 식이 단백질은 임의의 적절한 식이 단백질일 수 있다; 예를 들어, 동물성 단백질 (예컨대 밀크 단백질, 육류 단백질 또는 난 단백질); 식물성 단백질 (예컨대 대두 단백질, 밀 단백질, 쌀 단백질, 및 완두콩 단백질); 유리 아미노산의 혼합물; 또는 이들의 조합물. 밀크 단백질 예컨대 카제인, 유장 단백질 및 대두 단백질이 특히 바람직하다.In one embodiment, the nutritional composition contains a protein source. The protein source preferably provides about 5% to about 55% of the energy of the nutritional formulation; For example about 20% to about 50% of energy, preferably about 26%. Dietary protein is preferred as a protein source. The dietary protein may be any suitable dietary protein; Animal proteins (such as milk proteins, meat proteins or egg proteins); Vegetable proteins (such as soy protein, wheat protein, rice protein, and pea protein); Mixtures of free amino acids; Or combinations thereof. Milk proteins such as casein, whey protein and soy protein are particularly preferred.

조성물은 탄수화물 공급원 및 지방 공급원을 또한 함유한다.The composition also contains a carbohydrate source and a fat source.

지방 공급원은 바람직하게는 영양 제형물의 에너지의 약 5 % 내지 약 55 %를 제공한다; 예를 들어 에너지의 약 20 % 내지 약 50 %, 바람직하게는 23 %. 지방 공급원을 구성하는 지질은 임의의 적절한 지방 또는 지방 혼합물일 수 있다. 식물성 지방이 특히 적절하다; 예를 들어, 대두유, 팜유, 코코넛유, 홍화유, 해바라기유, 옥수수유, 카놀라유, 레시틴 등. 가장 바람직하게는, 카놀라 및 대두유의 혼합물이다. 동물성 지방 예컨대 밀크 지방 또한 원한다면 첨가될 수 있다.The fat source preferably provides about 5% to about 55% of the energy of the nutritional formulation; For example from about 20% to about 50% of energy, preferably 23%. The lipids constituting the fat source can be any suitable fat or fat mixture. Vegetable fats are particularly suitable; For example, soybean oil, palm oil, coconut oil, safflower oil, sunflower oil, corn oil, canola oil, lecithin and the like. Most preferably, it is a mixture of canola and soybean oil. Animal fats such as milk fat may also be added if desired.

바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 1 % 내지 약 5 %, 더욱 바람직하게는 2.5 %를 이루는 포화 지방을 함유한다. 바람직하게는, 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 약 9.9 %를 이루는 단일불포화 지방을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 10.1 %를 이루는 다중불포화 지방을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 5 % 내지 약 15 %, 더욱 바람직하게는 8.5 %를 이루는 리놀산을 함유한다. 바람직하게는, 조성물은 제품의 전체 에너지의 바람직하게는 약 0.5 % 내지 약 5 %, 더욱 바람직하게는 1.6 %를 이루는 리놀렌산을 함유한다. 바람직하게는, 리놀산 대 리놀렌산의 비는 약 3 내지 약 8, 더욱 바람직하게는 약 5.3이다.Preferably, the composition contains saturated fats, preferably from about 1% to about 5%, more preferably 2.5% of the total energy of the product. Preferably, it contains monounsaturated fats, preferably from about 5% to about 15%, more preferably about 9.9% of the total energy of the product. Preferably, the composition contains polyunsaturated fats, preferably from about 5% to about 15%, more preferably 10.1% of the total energy of the product. Preferably, the composition contains linoleic acid, which preferably comprises from about 5% to about 15%, more preferably 8.5% of the total energy of the product. Preferably, the composition contains linolenic acid, which preferably comprises from about 0.5% to about 5%, more preferably 1.6% of the total energy of the product. Preferably, the ratio of linoleic acid to linolenic acid is about 3 to about 8, more preferably about 5.3.

탄수화물 공급원은 영양 조성물의 에너지의 약 40 % 내지 약 80 %, 더욱 바람직하게는 약 51 %를 제공한다. 임의의 적절한 탄수화물, 예를 들어, 수크로스, 락토스, 글루코스, 프룩토스, 옥수수 시럽 고형분, 말토덱스트린 또는 이들의 혼합물을 사용할 수 있다.The carbohydrate source provides about 40% to about 80%, more preferably about 51% of the energy of the nutritional composition. Any suitable carbohydrate can be used, such as sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin or mixtures thereof.

조성물의 이러한 구현예는 300 g의 조성물 당 약 10 E10 cfu의 파라카제이 또는 존스니이 균활성 젖산 박테리아 및 약 6 g의 프룩토올리고당 및 이눌린을 추가적으로 함유한다.This embodiment of the composition additionally contains about 10 E10 cfu of paracaze or John's S. fungal lactic acid bacteria and about 6 g of fructooligosaccharides and inulin per 300 g of the composition.

식이 섬유 또한 첨가될 수 있다. 바람직하게는, 식이 섬유는 영양 조성물의 에너지의 약 5 %까지를 제공한다. 식이 섬유는 임의의 적절한 기원, 바람직하게는 프룩토올리고당, 이눌린 또는 이들의 혼합물로부터 유래될 수 있다.Dietary fibers may also be added. Preferably, the dietary fiber provides up to about 5% of the energy of the nutritional composition. Dietary fibers may be derived from any suitable origin, preferably fructooligosaccharides, inulin or mixtures thereof.

추가적인 적절한 비타민 및 미네랄이 상기 기술된 바와 같은 본 발명의 조성물에 함유된다.Further suitable vitamins and minerals are contained in the compositions of the present invention as described above.

모노소듐 글루타메이트가 향미 증강제로서 첨가될 수 있다.Monosodium glutamate may be added as a flavor enhancer.

영양 조성물은 바람직하게는 장내 투여가능하다; 예를 들어, 분말, 액체 농축물, 또는 즉석(ready to drink) 음료의 형태. 분말화 영양 제형물을 제조하기 위해서는, 균질화 혼합물을 적절한 건조 장치 예컨대 분무 건조기 또는 동결 건조기에 옮기고, 분말로 전환시킨다.The nutritional composition is preferably administrable enteric; For example, in the form of a powder, liquid concentrate, or ready to drink beverage. To prepare a powdered nutritional formulation, the homogenization mixture is transferred to a suitable drying apparatus such as a spray dryer or lyophilizer and converted to a powder.

대안적으로, 통상적인 식품을 조성물의 구현예로 보강할 수 있다. 예를 들어, 발효유, 요구르트, 생치즈, 응유 밀크, 과자류의 물품, 예를 들어 가당 음료, 과자 바(bar), 아침식사용 곡류 플레이크 또는 바, 음료수, 밀크 파우더, 대두 기재품, 밀크가 아닌 발효 제품 또는 임상 영양용 영양 보충제. 이어서, 첨가된 조성물의 양은 바람직하게는 약 0.01 중량% 이상이다.Alternatively, conventional foods may be fortified with embodiments of the composition. For example, fermented milk, yoghurt, fresh cheese, curd milk, confectionary products, such as sweetened beverages, snack bars, breakfast cereal flakes or bars, beverages, milk powders, soy products, non-milk Fermented product or nutritional supplement for clinical nutrition. The amount of composition added is then preferably at least about 0.01% by weight.

하기의 실시예는 단지 예시를 위해서 주어지며, 결코 본 발명의 주제를 제한하는 것으로 해석되지 않아야 한다. 백분율 및 부는 달리 언급되지 않는 한 중량 기준이다.The following examples are given for illustrative purposes only and should never be construed as limiting the subject matter of the present invention. Percents and parts are by weight unless otherwise indicated.

실시예 1 및 2: 영양 조성물Examples 1 and 2: Nutritional Composition

필요한 구성성분들을 배합하여 2 개의 영양 조성물을 제조하였다. 이들의 조성을 표 1에 나타낸다. 조성물은 보강된 음료 또는 밀크 제품 디저트를 기초로 1일 당 2개의 경구 보충물의 형태로 소비되도록 의도된다. 전체 1일 용량은 약 300 g 또는 300 ㎎의 조성물이도록 의도된다.Two nutritional compositions were prepared by combining the required ingredients. These compositions are shown in Table 1. The composition is intended to be consumed in the form of two oral supplements per day based on the fortified beverage or milk product dessert. The total daily dose is intended to be about 300 g or 300 mg of the composition.

본원에 기술된 현재 바람직한 구현예의 다양한 변화 및 개질이 당업자에게 명백할 것이라는 것을 이해하여야 한다. 이같은 변화 및 개질은 본 발명의 취지 및 범주를 벗어나지 않으면서, 그리고 이의 부수적인 장점을 손상시키지 않으면서 이루어질 수 있다. 따라서, 이같은 변화 및 개질은 첨부되는 청구항에 의해 커버되는 것으로 의도된다.It should be understood that various changes and modifications of the presently preferred embodiments described herein will be apparent to those skilled in the art. Such changes and modifications can be made without departing from the spirit and scope of the invention and without detracting from its attendant advantages. Accordingly, such changes and modifications are intended to be covered by the appended claims.

Claims (18)

단백질 공급원, 탄수화물 공급원, 지방 공급원, 균활성 젖산 박테리아 및 추가적으로 프룩토올리고당 및/또는 이눌린을 함유하는 조성물.A composition containing a protein source, a carbohydrate source, a fat source, a bacteriolytic lactic acid bacterium and additionally fructooligosaccharides and / or inulin. 제 1 항에 있어서, 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연 및 셀레늄으로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 함유하는 조성물.The composition of claim 1 containing at least one nutrient or mineral selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium. 제 2 항에 있어서, 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연 및 셀레늄으로 구성되는 군으로부터 선택되는 3 개 이상의 영양소 또는 미네탈을 함유하는 조성물.The composition of claim 2 containing at least three nutrients or minerals selected from the group consisting of vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium. 제 2 항 또는 제 3 항에 있어서, 비타민 E, 비타민 C, 비타민 B6, 엽산, 비타민 B12, 구리, 아연 및 셀레늄을 함유하는 조성물.4. A composition according to claim 2 or 3 containing vitamin E, vitamin C, vitamin B6, folic acid, vitamin B12, copper, zinc and selenium. 제 1 항 내지 제 4 항 중 어느 한 항에 있어서, 칼슘, 인, 마그네슘, 철, 비타민 A, 비타민 B1, 비타민 B2, 니아신 및 비타민 D로 구성되는 군으로부터 선택되는 하나 이상의 영양소 또는 미네랄을 함유하는 조성물.The composition according to any one of claims 1 to 4, containing at least one nutrient or mineral selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. Composition. 제 5 항에 있어서, 칼슘, 인, 마그네슘, 철, 비타민 A, 비타민 B1, 비타민 B2, 니아신 및 비타민 D로 구성되는 군으로부터 선택되는 3 개 이상의 영양소 또는 미네랄을 함유하는 조성물.6. The composition of claim 5 containing at least three nutrients or minerals selected from the group consisting of calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. 제 5 항 또는 제 6 항에 있어서, 칼슘, 인, 마그네슘, 철, 비타민 A, 비타민 B1, 비타민 B2, 니아신 및 비타민 D를 함유하는 조성물.7. A composition according to claim 5 or 6 containing calcium, phosphorus, magnesium, iron, vitamin A, vitamin B1, vitamin B2, niacin and vitamin D. 제 5 항 내지 제 7 항 중 어느 한 항에 있어서, 칼슘이 밀크 칼슘, 또는 밀크 칼슘으로부터 유래된 칼슘의 형태인 조성물.8. The composition of any one of claims 5 to 7, wherein the calcium is in the form of milk calcium or calcium derived from milk calcium. 제 1 항 내지 제 8 항 중 어느 한 항에 있어서, 파라카제이(paracasei) 및 존스니이(johnsonii) 박테리아로 구성되는 군으로부터 선택되는 하나 이상의 균활성 젖산 박테리아를 함유하는 조성물.The composition of claim 1, wherein the composition contains at least one bioactive lactic acid bacterium selected from the group consisting of paracasei and johnsonii bacteria. 10. 제 9 항에 있어서, 젖산 박테리아가 ST11 (명칭 NCCMI-2116으로 기탁됨) 및 La1 (명칭 NCCMI-1225로 기탁됨)으로 구성되는 군으로부터 선택되는 조성물.The composition of claim 9 wherein the lactic acid bacteria are selected from the group consisting of ST11 (deposited under the name NCCMI-2116) and La1 (deposited under the name NCCMI-1225). 제 1 항 내지 제 10 항 중 어느 한 항에 있어서, 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)을 함유하는 조성물:The composition according to any one of claims 1 to 10, which contains the following mass or amount of nutrients or minerals (if present) per 300 g of the composition: 비타민 E: 약 1 IU 내지 약 400 IU,Vitamin E: about 1 IU to about 400 IU, 비타민 C: 약 6 ㎎ 내지 약 300 ㎎,Vitamin C: about 6 mg to about 300 mg, 비타민 B6: 약 0.17 ㎎ 내지 약 3 ㎎,Vitamin B6: about 0.17 mg to about 3 mg, 엽산: 약 40 ㎍ 내지 약 800 ㎍,Folic acid: about 40 μg to about 800 μg, 비타민 B12: 약 0.24 ㎎ 내지 약 5 ㎎,Vitamin B12: about 0.24 mg to about 5 mg, 구리: 약 0.3 ㎎ 내지 약 3 ㎎,Copper: about 0.3 mg to about 3 mg, 아연: 약 1.5 ㎎ 내지 약 15 ㎎,Zinc: about 1.5 mg to about 15 mg, 셀레늄: 약 7 ㎍ 내지 약 300 ㎍,Selenium: about 7 μg to about 300 μg, 프룩토올리고당 및/또는 이눌린: 약 4 g 내지 약 50 g,Fructooligosaccharides and / or inulin: about 4 g to about 50 g, 젖산 박테리아: 약 10 E8 내지 약 10 E12 cfu.Lactic acid bacteria: about 10 E8 to about 10 E12 cfu. 제 1 항 내지 제 11 항 중 어느 한 항에 있어서, 조성물 300 g 당 하기 질량 또는 양의 영양소 또는 미네랄 (존재한다면)을 함유하는 조성물:The composition according to any one of claims 1 to 11, which contains the following mass or amount of nutrients or minerals (if present) per 300 g of the composition: 칼슘: 약 100 ㎎ 내지 약 300 ㎎,Calcium: about 100 mg to about 300 mg, 인: 약 50 ㎎ 내지 약 615 ㎍,Phosphorus: about 50 mg to about 615 μg, 마그네슘: 약 110 ㎎ 내지 약 210 ㎎,Magnesium: about 110 mg to about 210 mg, 비타민 A: 약 1000 IU 내지 약 1500 IU,Vitamin A: about 1000 IU to about 1500 IU, 비타민 D: 약 50 IU 내지 약 150 IU,Vitamin D: from about 50 IU to about 150 IU, 비타민 E: 약 5.0 IU 내지 약 150 IU,Vitamin E: about 5.0 IU to about 150 IU, 비타민 C: 약 30 ㎎ 내지 약 500 ㎎,Vitamin C: about 30 mg to about 500 mg, 비타민 B1: 약 0.1 ㎎ 내지 약 2 ㎎,Vitamin B1: about 0.1 mg to about 2 mg, 비타민 B2: 약 0.1 ㎎ 내지 약 0.6 ㎎,Vitamin B2: about 0.1 mg to about 0.6 mg, 니아신: 약 1.5 ㎎ 내지 약 7.2 ㎎,Niacin: about 1.5 mg to about 7.2 mg, 비타민 B6: 약 1.0 ㎎ 내지 약 3.0 ㎎,Vitamin B6: about 1.0 mg to about 3.0 mg, 엽산: 약 200 ㎍ 내지 약 600 ㎍,Folic acid: about 200 μg to about 600 μg, 비타민 B12: 약 1.5 ㎍ 내지 약 4.5 ㎍,Vitamin B12: about 1.5 μg to about 4.5 μg, 철: 약 2.0 ㎎ 내지 약 5 ㎎,Iron: about 2.0 mg to about 5 mg, 아연: 약 10 ㎎ 내지 약 20 ㎎.Zinc: about 10 mg to about 20 mg. 제 1 항 내지 제 12 항 중 어느 한 항에 있어서, 아카시아 고무를 함유하는 조성물.The composition according to any one of claims 1 to 12, which contains acacia rubber. 필요한 영양소를 필요한 양으로 함께 배합하는 단계를 포함하는, 제 1 항 내지 제 13 항 중 어느 한 항에 따른 조성물의 제조 방법.14. A process for the preparation of a composition according to any one of claims 1 to 13, comprising the step of combining the necessary nutrients together in the required amounts. 제 13 항에 있어서, 배합된 혼합물을 압출하고/압출하거나 혼합물을 분무 건조시키는 추가적인 단계를 포함하는 방법.The method of claim 13, comprising the further step of extruding the blended mixture and / or spray drying the mixture. 면역 상태의 예방 또는 치료에서의 제 1 항 내지 제 13 항 중 어느 한 항에 따른 조성물의 용도.Use of a composition according to any one of claims 1 to 13 in the prevention or treatment of an immune condition. 면역 상태의 예방 또는 치료를 위한 기능성 식품 또는 의약의 제조에서의 제 1 항 내지 제 13 항 중 어느 한 항에 따른 조성물의 용도.Use of a composition according to any one of claims 1 to 13 in the manufacture of a functional food or medicament for the prevention or treatment of an immune condition. 유효량의 제 1 항 내지 제 13 항 중 어느 한 항에 따른 조성물을 투여하는 것을 포함하는, 면역 상태의 예방 또는 치료 방법.A method for preventing or treating an immune condition, comprising administering an effective amount of the composition according to any one of claims 1 to 13.
KR10-2003-7006389A 2000-11-14 2001-11-14 Nutritional composition for an immune condition KR20030051802A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0027761.6A GB0027761D0 (en) 2000-11-14 2000-11-14 Nutritional composition for an immune condition
GB0027761.6 2000-11-14
PCT/EP2001/013302 WO2002039834A1 (en) 2000-11-14 2001-11-14 Nutritional composition for an immune condition

Publications (1)

Publication Number Publication Date
KR20030051802A true KR20030051802A (en) 2003-06-25

Family

ID=9903140

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7006389A KR20030051802A (en) 2000-11-14 2001-11-14 Nutritional composition for an immune condition

Country Status (20)

Country Link
US (2) US6929793B2 (en)
EP (1) EP1339294B2 (en)
JP (1) JP2004513898A (en)
KR (1) KR20030051802A (en)
CN (2) CN103181564A (en)
AT (1) ATE336909T1 (en)
AU (2) AU2002221860B2 (en)
BR (1) BR0115311A (en)
CA (1) CA2427385C (en)
DE (1) DE60122570T3 (en)
ES (1) ES2269514T5 (en)
GB (1) GB0027761D0 (en)
IL (1) IL155674A (en)
MX (1) MXPA03004268A (en)
NO (1) NO326348B1 (en)
PL (1) PL201161B1 (en)
RU (1) RU2289955C2 (en)
UA (1) UA78196C2 (en)
WO (1) WO2002039834A1 (en)
ZA (1) ZA200304605B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103478716A (en) * 2013-09-23 2014-01-01 南昌大学 Preparation method for functional food with immunity enhancing effect
KR101388395B1 (en) * 2008-01-10 2014-04-22 뉴트리 가부시키가이샤 Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7029702B2 (en) * 1998-07-07 2006-04-18 Ritter Natural Sciences Llc Method for increasing lactose tolerance in mammals exhibiting lactose intolerance
ATE403718T1 (en) * 2002-04-09 2008-08-15 Nestle Sa LA1- THE GENOME OF A LACTOBACILLUS STRAIN
JP2004059488A (en) * 2002-07-29 2004-02-26 Asahi Food & Healthcare Ltd Lactobacillus intestinal disorder controlling composition and food
AU2003266285A1 (en) * 2002-08-16 2004-03-11 Finzelberg Gmbh And Co. Kg Medicament, food supplement, and fodder additive
GB2395627B (en) * 2002-11-21 2006-05-10 Hewlett Packard Co Detector
JP2007527400A (en) * 2003-07-15 2007-09-27 ネステク ソシエテ アノニム High fiber high calorie liquid or powder nutritional composition
GB0330009D0 (en) 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
US20050245398A1 (en) * 2004-04-29 2005-11-03 Healthy Soils, Inc. Biological composition for enhancing vegetation growth
WO2006012536A2 (en) * 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
US20100233312A9 (en) * 2005-04-11 2010-09-16 The Procter & Gamble Company Compositions comprising probiotic and sweetener components
ES2561629T3 (en) 2005-09-28 2016-02-29 Nordisk Rebalance A/S Treatment of IBS using both probiotic bacteria and fermented cereals as effectors of treatment
ZA200802935B (en) * 2005-10-06 2009-11-25 Brobi Ab Use of lactobacillus for treatment of autoimmune diseases
ATE541469T1 (en) * 2005-12-29 2012-02-15 Hills Pet Nutrition Inc METHOD FOR MODIFYING THE INTESTINAL FLORA IN ANIMALS
US20070196439A1 (en) * 2006-02-13 2007-08-23 Catani Steven J Lactose-reduced dairy compositions and related methods
EP2021457B1 (en) 2006-05-28 2015-02-11 Cipla Medpro Research And Development (Pty) Ltd Probiotic strain and antimicrobial peptide derived therefrom
US20080038432A1 (en) * 2006-08-14 2008-02-14 Hoffman Andrew J Food Additive Comprising at Least One Fiber Source and at Least One Monosaccharide or Sugar Alcohol
DK1992351T3 (en) 2007-05-18 2016-06-06 Nestec Sa Lactobacillus johnsonii for the prevention of post-surgical infection
WO2009004409A1 (en) * 2007-06-29 2009-01-08 Sirc - Natural & Dietetic Foods S.R.L. Preparations contaning microorganisms
MX2010003090A (en) * 2007-09-21 2010-04-09 Kerry Group Services Int Ltd A probiotic composition.
US20110223248A1 (en) * 2007-12-12 2011-09-15 Ritter Pharmaceuticals, Inc. Methods and compositions for treating lactose intolerance
US20110189148A1 (en) * 2008-06-25 2011-08-04 Ritter Pharmaceuticals, Inc. Lactose compositions with decreased lactose content
US20100004334A1 (en) * 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
EP2373185B1 (en) 2009-01-02 2018-08-08 Nestec S.A. Food compositions having a realistic meat-like appearance, feel and texture
SG2014014435A (en) 2009-02-24 2014-07-30 Ritter Pharmaceuticals Inc Prebiotic formulations and methods of use
US20100233347A1 (en) * 2009-03-13 2010-09-16 Uhrhan Richard B Food compositions having a realistic meat-like appearance, feel, and texture
WO2011137249A1 (en) 2010-04-28 2011-11-03 Ritter Pharmaceuticals, Inc. Prebiotic formulations and methods of use
CN101828718B (en) * 2010-04-29 2012-12-26 北京世纪劲得保健品有限公司 High-fiber fruit and vegetable nutrition package and preparation method thereof
ES2627115T3 (en) 2010-05-26 2017-07-26 Nestec S.A. Procedures to increase the production or activity of catalase
EP2397145A1 (en) * 2010-06-18 2011-12-21 Nestec S.A. L. johnsonii La1, B. longum NCC2705 and immune disorders
US20120015075A1 (en) * 2010-07-13 2012-01-19 Hero Nutritionals, LLC Chewable supplement with live microorganisms
US20140023656A1 (en) * 2010-09-24 2014-01-23 BioLT CO., LTD. Pharmaceutical composition for treatment and prevention of th3 march-related diseases
US9320759B2 (en) 2011-01-25 2016-04-26 Nestec S.A Methods and compositions for treating, reducing or preventing deterioration of the visual system of animals
SG192692A1 (en) * 2011-02-07 2013-09-30 Abbott Lab Nutritional products comprising beta-hydroxy-beta-methylbutyrate
MX359453B (en) 2011-03-18 2018-09-28 Nestec Sa Compositions and methods useful for ameliorating age related maladies.
EP2898923A3 (en) 2011-04-15 2015-10-07 Nestec S.A. Isoflavones for regulating sirtuin gene expression
US10039296B2 (en) 2011-06-20 2018-08-07 H.J. Heinz Company Brands Llc Probiotic compositions and methods
RU2485964C1 (en) * 2012-01-10 2013-06-27 Сергей Александрович Староверов Immunostimulating composition for animals
US20140037813A1 (en) * 2012-08-02 2014-02-06 Mead Johnson Nutrition Company Nutritional creamer composition
NZ711956A (en) 2013-03-08 2018-06-29 Axiom Foods Inc Rice protein supplements
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
PL2994150T3 (en) 2013-05-10 2019-09-30 H.J. Heinz Company Brands Llc Probiotics and methods of use
CA2930348C (en) 2013-12-20 2023-03-07 Nestec S.A. Nutritional compositions for reducing intestinal pathogens
US20170056462A1 (en) * 2014-04-25 2017-03-02 Nexira International Use of a composition comprising arabic gum (ag) for improving gut impermeability
PL3197297T3 (en) * 2014-09-23 2021-06-14 Dom Terry International S.R.L. Prebiotic inulin based preparation
CN104432104A (en) * 2014-11-05 2015-03-25 江南大学 Preparation method of salty high-protein probiotic nutrition bar
CN107072254A (en) 2014-11-25 2017-08-18 雀巢产品技术援助有限公司 For the method and composition for lifting lean body mass, minimizing body fat increase and management weight
RU2693659C2 (en) 2014-11-25 2019-07-03 Нестек Са Methods and compositions for preserving lean body weight and stimulating fat loss during weight loss
US10294157B2 (en) 2015-08-25 2019-05-21 Nippon Shokubai Co., Ltd. Cement additive, cement composition, and cement additive raw material
CN105661017A (en) * 2016-02-03 2016-06-15 程雪娇 Livestock feed and preparation method
US9855305B2 (en) 2016-03-29 2018-01-02 Companion Therapeutics Llc Pharmaceutical composition containing combinations of vitamins, minerals, probiotics, and prebiotics effective in preventing adverse effects associated with the use of proton-pump inhibitors
CN110868870A (en) 2017-05-12 2020-03-06 艾斯姆食品公司 Rice products and systems and methods for making same
US20220007685A1 (en) 2018-10-18 2022-01-13 Hill's Pet Nutrition, Inc. Pet Food Compositions
CN113163801A (en) 2018-12-13 2021-07-23 雀巢产品有限公司 Methods for enhancing metabolic health in animals
EP3893662A1 (en) 2018-12-13 2021-10-20 Société des Produits Nestlé S.A. Methods for increasing fat oxidation or energy expenditure or satiety in an animal
WO2020148391A1 (en) 2019-01-16 2020-07-23 N.V. Nutricia Fermented formula with non-digestible oligosaccharides for use in rotavirus induced infection
CA3164927A1 (en) 2019-12-19 2021-06-24 Societe Des Produits Nestle S.A. Compositions and methods for providing a health benefit to a growing animal
CN111329046A (en) * 2020-03-13 2020-06-26 上海复旦奥医医学科技有限公司 Special clinical nutrition formula for nasopharyngeal carcinoma and preparation method thereof
AU2021336099A1 (en) 2020-09-03 2023-02-23 Societe Des Produits Nestle Sa Compositions and methods for providing health benefits in an animal
US11896581B2 (en) 2020-09-04 2024-02-13 Société des Produits Nestlé S.A. Compositions and methods for providing health benefits in an animal
CN116568151A (en) 2020-12-11 2023-08-08 雀巢产品有限公司 Compositions and methods for pet foods
US20230165277A1 (en) 2021-11-29 2023-06-01 Société des Produits Nestlé S.A. Methods and compositions for providing a health benefit in an animal
US20230165281A1 (en) 2021-11-29 2023-06-01 Société des Produits Nestlé S.A. Methods and compositions for providing a health benefit in an animal
CN114848682A (en) * 2022-03-11 2022-08-05 中南大学湘雅三医院 Vitamin B6+ probiotic mixture and application thereof in preparation of medicines for relieving stress-related secondary injury and aseptic inflammation
WO2024057113A1 (en) 2022-09-13 2024-03-21 Societe Des Produits Nestle Sa Methods for providing and determining an efficacious weight loss diet for a canine
US20240081374A1 (en) 2022-09-14 2024-03-14 Société des Produits Nestlé S.A. Compositions and methods utilizing southern ocean mackerel oil for providing health benefits in an animal

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54129163A (en) 1978-03-28 1979-10-06 Fujiya Kk Production of instant yogurt powder
DE3727946A1 (en) 1987-08-21 1989-03-02 Werner Georg Munk RECONSTITUTABLE DRY PRODUCT FOR DIRECT CONSUMPTION, METHOD FOR THE PRODUCTION THEREOF AND ITS USE
CH680192A5 (en) 1989-12-13 1992-07-15 Nestle Sa
JP3347381B2 (en) * 1993-01-27 2002-11-20 協和醗酵工業株式会社 Pet food
US5565630A (en) 1993-11-17 1996-10-15 Monaghan Medical Corporation Peak flow meter
JP2973844B2 (en) 1994-04-27 1999-11-08 不二製油株式会社 Manufacturing method of cream cheese-like food
JPH08126473A (en) * 1994-09-08 1996-05-21 Fuji Oil Co Ltd Oily composition, its production and oily coated confectionery using the same
US6241983B1 (en) * 1994-10-28 2001-06-05 Metagenics, Inc. Bacteria-and fiber-containing composition for human gastrointestinal health
AUPN881396A0 (en) * 1996-03-20 1996-04-18 Arnott's Biscuits Limited Enhancement of microbial colonization of the gastrointestinal tract
ES2184847T5 (en) * 1996-07-31 2007-03-01 "RAFFINERIE TIRLEMONTOISE", SOCIETE ANONYME LACTIC POWDERS CONTAINING FRUCTANE AND / OR POLYDEXTROSA, PROCEDURE FOR PREPARATION AND USE.
JP4065038B2 (en) 1996-08-07 2008-03-19 カルピス株式会社 Computational workload stress relievers
CZ300387B6 (en) * 1997-07-05 2009-05-06 Societe Des Produits Nestle S. A. Use of Lactobacillus bacteria
CN1208620A (en) * 1997-08-15 1999-02-24 陈秀枢 Composite contg. bacterium bifidum and lactobacillus
EP0904784A1 (en) * 1997-09-22 1999-03-31 N.V. Nutricia Probiotic nutritional preparation
US6093425A (en) * 1997-11-21 2000-07-25 Princeton Nutrition, L.L.C. Complete nutritional milk compositions and products
US6117477A (en) * 1998-03-18 2000-09-12 Kal Kan Foods, Inc. Multicomponent food product and methods of making and using the same
JP2002523025A (en) * 1998-08-21 2002-07-30 アドヴァンスト・ニュートリショナル・フーズ・プロプライエタリー・リミテッド Composition
ATE308254T1 (en) * 1998-12-15 2005-11-15 Nestle Sa FIBER MIXTURE FOR ENTERAL COMPOSITION
CA2281463A1 (en) * 1999-08-26 2001-02-26 Stanley H. Zlotkin Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics
GB2369777B (en) * 2000-10-05 2004-10-27 St Ivel Ltd Food products with antimicrobial lactic acid bacteria
GB0100273D0 (en) * 2001-01-08 2001-02-14 Nestle Sa Nutritional composition for a bone condition

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101388395B1 (en) * 2008-01-10 2014-04-22 뉴트리 가부시키가이샤 Composition for improving nutritional status, reducing frequency of fever and/or increasing immunocompetence of elderly
CN103478716A (en) * 2013-09-23 2014-01-01 南昌大学 Preparation method for functional food with immunity enhancing effect

Also Published As

Publication number Publication date
GB0027761D0 (en) 2000-12-27
JP2004513898A (en) 2004-05-13
ES2269514T3 (en) 2007-04-01
NO20032129L (en) 2003-07-11
DE60122570T3 (en) 2015-05-21
CA2427385A1 (en) 2002-05-23
NO326348B1 (en) 2008-11-17
EP1339294B2 (en) 2015-01-21
CN103181564A (en) 2013-07-03
DE60122570T2 (en) 2007-09-20
US20050208035A1 (en) 2005-09-22
CN1503632A (en) 2004-06-09
PL201161B1 (en) 2009-03-31
NO20032129D0 (en) 2003-05-12
US6929793B2 (en) 2005-08-16
RU2289955C2 (en) 2006-12-27
ATE336909T1 (en) 2006-09-15
DE60122570D1 (en) 2006-10-05
AU2186002A (en) 2002-05-27
MXPA03004268A (en) 2004-04-21
ZA200304605B (en) 2004-09-13
BR0115311A (en) 2004-01-06
WO2002039834A1 (en) 2002-05-23
ES2269514T5 (en) 2015-04-01
EP1339294A1 (en) 2003-09-03
AU2002221860B2 (en) 2006-08-10
IL155674A (en) 2005-07-25
CA2427385C (en) 2010-05-04
IL155674A0 (en) 2003-11-23
US20040005305A1 (en) 2004-01-08
PL362438A1 (en) 2004-11-02
UA78196C2 (en) 2007-03-15
EP1339294B1 (en) 2006-08-23

Similar Documents

Publication Publication Date Title
US6929793B2 (en) Nutritional composition for treating an immune condition
AU2002221860A1 (en) Nutritional composition for an immune condition
EP1841330B1 (en) Use of infant formula with reduced protein content
EP0745333B1 (en) Nutritional compositions in various forms
EP2645883B1 (en) Staged infant feeding regimen to promote healthy development and growth
MX2011003179A (en) Nutritional composition to promote healthy development and growth.
US20080274127A1 (en) Amino acid supplementation for a healthy microbiota ecosystem
EP1351584A2 (en) Nutritional composition for a bone condition
AU2011100142A4 (en) Infant Formula: Probiotic Supplementation
JP2019081733A5 (en)
Lloyd US whey products and child nutrition
JPH1146720A (en) Nutritive composition for promoting absorption of calcium
Singh DAIRY NUTRACEUTICALS AND FUNCTIONAL DAIRY FOODS: CURRENT STATUS, ISSUES AND CHALLENGES
IES970234A2 (en) Food Product

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid